JSJürgen Schölmerich

Jürgen Schölmerich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jürgen Schölmerich has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evolving Concepts in IBD Therapy: What Should Be Studied in the Future?

    by Jürgen Schölmerich

    New knowledge regarding the etiopathophysiology of inflammatory bowel diseases (IBD) may provide new approaches for treatment. The most convincing concept at the moment is a defective mucosal barrier due to inappropriate recognition of the luminal flora or to a defective defense against those bacteria. These concepts indicate that the paradigm of immune suppression may not be the optimal concept. Therefore variable approaches to improve the barrier function or to modulate luminal components have to be studied in the future. This includes probiotics, bile acid receptor agonists, Toll-like receptor agonists and many other as yet hypothetical ideas. We still have much to learn about the concepts mentioned in order to achieve the goals of treatment, i.e. avoiding structural damage and complications.


  • Open Access

    Sequential Combination Therapy Leading to Sustained Remission in a Patient with SAPHO Syndrome

    by C.E Huber, A.G Judex, J Freyschmidt, S Feuerbach, J Schölmerich, U Müller-Ladner

    The SAPHO syndrome represents a variety of clinically similar disorders with the key features of hyperostotic bone lesions in combination with chronic pustular skin disease. The respective pathophysiology of bone and joint manifestations in SAPHO syndrome is still a matter of discussion. For example it does not appear to represent reactive arthritis and HLA B27 antigen, with the latter being typically present in patients with spondyloarthopathies. Treatment of SAPHO syndrome is also not well established and consists of various antiinflammatory and antirheumatic drugs. Here, we report a female patient with active SAPHO syndrome suffering from sternal swelling of unknown origin that had been known for 10 years and a 4-year-history of severe lower back pain. Remarkable were also a typical pustulous palmar erythema associated with swelling and decreased motility of both MCP-I joints. Inflammation parameters were high with an ESR 68 mm/1st hour and a CRP of 19.6 mg/l. She was initially treated with rofecoxib and doxycycline, followed by sulfasalazine with only partial clinical response. Thereafter, both articular symptoms as well as cutaneous lesions responded well to a combination therapy with methotrexate and sulfasalazine. Thus, the case illustrates nicely that methotrexate in combination with another DMARD can be successfully applied to patients with long-term active SAPHO syndrome.


  • Balancing the risks and benefits of prolonged use of infliximab

    by Jürgen Schölmerich

    The second report (see page 501) assessed medical records of 734 patients with inflammatory bowel disease (IBD), the majority with Crohn’s disease, treated with infliximab during 14 years, and compared them with 666 patients who did not receive infliximab followed during this period.2 Median follow-up was more than twice as long for controls than for infliximab patients (58 months; 33–88 months). A total of 113 severe adverse events occurred in 93 treated patients, and 157 in 126 control patients. Mortality, malignancies and infection rates did not differ between the two populations. However, the control group was older and received steroids much more often during the much longer follow-up.


  • Open Access

    Risk factors for negative blood cultures in adult medical inpatients – a retrospective analysis

    by Boris P Ehrenstein, Vera Ehrenstein, Christine Henke, Hans-Jörg Linde, Bernd Salzberger, Jürgen Schölmerich, Thomas Glück

    The identification of clinical factors associated with negative blood cultures could help to avoid unnecessary blood cultures. C-reactive protein (CRP) is a well-established inflammation marker commonly used in the management of medical inpatients.


  • Therapie bei chronisch-entzündlichen Darmerkrankungen

    by J Schölmerich

    Die Standardtherapie bei entzündlichen Darmerkrankungen mit 5-Aminosalicylsäure, Steroiden und Immunsuppressiva ist erfreulich wirksam und wird noch optimiert, beispielsweise durch Kombinationen von Substanzen oder Applikationsformen. Von den biologischen Therapien ist bislang nur Infliximab in das therapeutische Arsenal gelangt, es wirkt auch bei einigen Patienten mit Colitis ulcerosa. Eine frühe aggressive Therapie ist bislang nicht etabliert. Hormone und Wachstumsfaktoren können eine Rolle spielen. Probiotika nehmen einen Platz in der Therapie insbesondere bei Colitis ulcerosa ein.


  • Open Access

    Review article: should we treat symptoms or lesions in Crohn's disease? The case for treating symptoms

    by J. Schölmerich

    Summary: Apart from treating symptoms, mucosal healing is a reasonable aim of therapy in Crohn's disease. In most patients, however, the disease takes a mild course and treating symptoms seems sufficient. Eliminating lesions may change the course of the disease long‐term but this has not yet been proven. Thus far we need to treat symptoms efficiently and may attempt to restore bacterial epithelial interaction.


  • Inflammatory Bowel Disease

    by Jürgen Schölmerich

    Abstract:  Current treatment of inflammatory bowel disease is rather effective through it is only working in symptomatic fashion. Most recombinant “biologicals” have not been an overwhelming success. Infliximab has shown clinically relevant efficacy and is used in patients not responding to the standards. Alternatives such as modulating the bacterial‐epithelial interaction, tightening of the mucosal barrier and maybe even immunostimulation should be studied since most recent finding on etiology and pathophysiology point to a disturbed barrier with consequent abnormal bacterial epithelial interaction as the main problem in the IBD syndrome. We still need to learn much but we should not focus only on immunosuppressive systems.


  • Nonsteroidal Anti-inflammatory Drugs Versus Selective COX-2 Inhibitors in the Upper Gastrointestinal Tract

    by Jürgen Schölmerich

    There are enough basic data supporting the use of coxibs with regard to the upper GI tract in patients with the need for continuous treatment of joint pain. The clinical studies available clearly show that coxibs induce fewer lesions and complications in volunteers and in patients when compared with NSAIDs. However, in Helicobacter pylori- positive patients the advantage seems less clear. The combination of NSAID plus PPI is not worse with regard to duodenal ulcers and recurrent clinical complications and is more cost effective than the use of coxibs. Similarly, with the concomitant use of aspirin even in low doses no major advantage of coxibs has been demonstrated. The combination of coxibs and PPI in high-risk patients needs to be studied. It is unclear at the moment how important are the changes in the lower GI tract. Considering the current controversy regarding cardiovascular events, there is no major reason to prefer coxibs to conventional NSAID plus PPI in patients needing long-term treatment.

  • Therapie von Komplikationen chronisch entzündlicher Darmerkrankungen

    by J Schölmerich

    Komplikationen von chronisch entzündlichen Darmerkrankungen sind aufgrund verbesserter konservativer und chirurgischer Therapie eher selten. Sie werden zudem durch die heutigen diagnostischen Verfahren besser erkannt und klassifiziert und sind damit einer Therapie besser zugänglich. Grössere Statistiken zeigen, dass das Überleben der Patienten zwar noch nicht völlig normalisiert ist, allerdings ist nur ein kleiner Teil der Todesfälle tatsächlich durch die chronisch entzündliche Darmerkrankung bedingt. Für die verschiedenen Komplikationen wie toxisches Megakolon, schwere Blutung, Stenose und Ileus, Fisteln und Abszesse stehen trotz Fehlen von grösseren kontrollierten Studien klare Therapiemassnahmen zur Verfügung, deren Kenntnis auch durch den primär behandelnden Arzt erforderlich ist, um die Patienten einer adäquaten Behandlung an geeigneter Stelle zuzuführen. Bezüglich der Neoplasien scheinen früher vorgelegte Zahlen aufgrund der heutigen Therapiemassnahmen nicht mehr haltbar zu sein, eine konsequente Betreuung und Behandlung im Sinne einer Rezidivprophylaxe scheint diese Komplikation weitgehend zu eliminieren.